JAZZ Relative Valuation
JAZZ's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, JAZZ is overvalued; if below, it's undervalued.
Historical Valuation
Jazz Pharmaceuticals PLC (JAZZ) is now in the Undervalued zone, suggesting that its current forward PE ratio of 7.50 is considered Undervalued compared with the five-year average of 8.00. The fair price of Jazz Pharmaceuticals PLC (JAZZ) is between 370.35 to 454.56 according to relative valuation methord. Compared to the current price of 167.10 USD , Jazz Pharmaceuticals PLC is Undervalued By 54.88%.
Relative Value
Fair Zone
370.35-454.56
Current Price：167.10
54.88%
Undervalued
7.49
PE
1Y
3Y
5Y
Trailing
Forward
8.94
EV/EBITDA
Jazz Pharmaceuticals PLC. (JAZZ) has a current EV/EBITDA of 8.94. The 5-year average EV/EBITDA is 7.58. The thresholds are as follows: Strongly Undervalued below 4.85, Undervalued between 4.85 and 6.22, Fairly Valued between 8.94 and 6.22, Overvalued between 8.94 and 10.30, and Strongly Overvalued above 10.30. The current Forward EV/EBITDA of 8.94 falls within the Overvalued range.
7.06
EV/EBIT
Jazz Pharmaceuticals PLC. (JAZZ) has a current EV/EBIT of 7.06. The 5-year average EV/EBIT is 7.87. The thresholds are as follows: Strongly Undervalued below 4.66, Undervalued between 4.66 and 6.26, Fairly Valued between 9.48 and 6.26, Overvalued between 9.48 and 11.09, and Strongly Overvalued above 11.09. The current Forward EV/EBIT of 7.06 falls within the Historic Trend Line -Fairly Valued range.
2.33
PS
Jazz Pharmaceuticals PLC. (JAZZ) has a current PS of 2.33. The 5-year average PS is 2.21. The thresholds are as follows: Strongly Undervalued below 1.25, Undervalued between 1.25 and 1.73, Fairly Valued between 2.70 and 1.73, Overvalued between 2.70 and 3.18, and Strongly Overvalued above 3.18. The current Forward PS of 2.33 falls within the Historic Trend Line -Fairly Valued range.
9.37
P/OCF
Jazz Pharmaceuticals PLC. (JAZZ) has a current P/OCF of 9.37. The 5-year average P/OCF is 6.85. The thresholds are as follows: Strongly Undervalued below 3.43, Undervalued between 3.43 and 5.14, Fairly Valued between 8.55 and 5.14, Overvalued between 8.55 and 10.26, and Strongly Overvalued above 10.26. The current Forward P/OCF of 9.37 falls within the Overvalued range.
7.43
P/FCF
Jazz Pharmaceuticals PLC. (JAZZ) has a current P/FCF of 7.43. The 5-year average P/FCF is 6.63. The thresholds are as follows: Strongly Undervalued below 3.69, Undervalued between 3.69 and 5.16, Fairly Valued between 8.11 and 5.16, Overvalued between 8.11 and 9.58, and Strongly Overvalued above 9.58. The current Forward P/FCF of 7.43 falls within the Historic Trend Line -Fairly Valued range.
Jazz Pharmaceuticals PLC (JAZZ) has a current Price-to-Book (P/B) ratio of 2.56. Compared to its 3-year average P/B ratio of 2.16 , the current P/B ratio is approximately 18.88% higher. Relative to its 5-year average P/B ratio of 2.31, the current P/B ratio is about 10.84% higher. Jazz Pharmaceuticals PLC (JAZZ) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of 15.79%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of 13.09% , the current FCF yield is about -100.00% lower.
2.56
P/B
Median3y
2.16
Median5y
2.31
13.16
FCF Yield
Median3y
15.79
Median5y
13.09
Competitors Valuation Multiple
The average P/S ratio for JAZZ's competitors is , providing a benchmark for relative valuation. Jazz Pharmaceuticals PLC Corp (JAZZ) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 6.74%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of JAZZ increased by 35.53% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -23.12 to -27.56.
The secondary factor is the Margin Expansion, contributed 9.57%to the performance.
Overall, the performance of JAZZ in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch
FAQ
Is Jazz Pharmaceuticals PLC (JAZZ) currently overvalued or undervalued?
What is Jazz Pharmaceuticals PLC (JAZZ) fair value?
How does JAZZ's valuation metrics compare to the industry average?
What is the current P/B ratio for Jazz Pharmaceuticals PLC (JAZZ) as of Dec 05 2025?
What is the current FCF Yield for Jazz Pharmaceuticals PLC (JAZZ) as of Dec 05 2025?
What is the current Forward P/E ratio for Jazz Pharmaceuticals PLC (JAZZ) as of Dec 05 2025?